Axitinib is a small molecule commercialized by Ocular Therapeutix, with a leading Phase III program in Wet (Neovascular / Exudative) Macular Degeneration. According to Globaldata, it is involved in 6 clinical trials, of which 2 were completed, 2 are ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Axitinibs valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Axitinib is expected to reach an annual total of $318 mn by 2035 in the US based off GlobalDatas Expiry Model. The drugs revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drugs phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Axitinib Overview
Axitinib (OTX-TKI) is under development for the treatment of wet age-related macular degeneration (AMD), moderately severe to severe non-proliferative diabetic retinopathy, diabetic macular edema, and retinal vein occlusion. It is a sustained release formulation administered through intravitreal injection. It acts by targeting tyrosine kinase. It is being developed based on ELUTYX technology.
Ocular Therapeutix Overview
Ocular Therapeutix is a biopharmaceutical company that discovers, develops and commercializes therapies for treating eye diseases. The companys pipeline products include DEXTENZA is used for the treatment of post-surgical Ocular inflammation and pain. Its pipeline products include OTX-TP, used for treating glaucoma and Ocular hypertension, OTX-BPI, targeting acute Ocular pain, OTX-BDI, against post-op pain, inflammation and anti-bacterial infections; OTX-KTO for treating allergic conjunctivitis; OTX-CSI, against dry eye. Ocular Therapeutix also develops intracameral implants for treating multiple eye disorders. The company works in collaboration with Regeneron Pharmaceuticals Inc to develop formulations for the treatment of wet AMD and other serious retinal diseases. Ocular Therapeutix is headquartered in Bedford, Massachusetts, the US.
The company reported revenues of (US Dollars) US$58.4 million for the fiscal year ended December 2023 (FY2023), an increase of 13.5% over FY2022. The operating loss of the company was US$68.2 million in FY2023, compared to an operating loss of US$78.7 million in FY2022. The net loss of the company was US$80.7 million in FY2023, compared to a net loss of US$71 million in FY2022.
The company reported revenues of US$14.8 million for the first quarter ended March 2024, a decrease of 0.2% over the previous quarter.
For a complete picture of Axitinibs valuation, buy the drugs risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
